Repligen Co. (NASDAQ:RGEN - Free Report) - Research analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of Repligen in a research note issued on Thursday, February 20th. Leerink Partnrs analyst P. Souda now forecasts that the biotechnology company will post earnings per share of $0.35 for the quarter, down from their prior forecast of $0.39. The consensus estimate for Repligen's current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen's Q4 2025 earnings at $0.51 EPS, FY2025 earnings at $1.72 EPS and FY2026 earnings at $2.33 EPS.
A number of other equities research analysts have also weighed in on RGEN. StockNews.com lowered shares of Repligen from a "hold" rating to a "sell" rating in a research note on Friday, February 21st. JPMorgan Chase & Co. lifted their target price on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. Finally, TD Cowen assumed coverage on shares of Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 price objective on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $181.00.
Get Our Latest Research Report on RGEN
Repligen Trading Down 3.9 %
Shares of RGEN traded down $6.27 during trading hours on Monday, reaching $156.54. 438,659 shares of the company traded hands, compared to its average volume of 616,050. The company's fifty day moving average price is $155.68 and its two-hundred day moving average price is $148.65. The company has a market capitalization of $8.77 billion, a price-to-earnings ratio of -306.94, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a 12 month low of $113.50 and a 12 month high of $203.13.
Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in RGEN. Champlain Investment Partners LLC lifted its stake in shares of Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock worth $211,464,000 after buying an additional 850,345 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after purchasing an additional 743,815 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Repligen by 183.1% during the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock valued at $132,227,000 after purchasing an additional 594,189 shares during the last quarter. Groupama Asset Managment raised its holdings in shares of Repligen by 12,321.0% during the fourth quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock valued at $58,142,000 after purchasing an additional 400,680 shares during the last quarter. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Repligen during the fourth quarter valued at approximately $53,428,000. Institutional investors own 97.64% of the company's stock.
About Repligen
(
Get Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Articles
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
